FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019944441> ?p ?o ?g. }

• W2019944441 endingPage "103" @default.
• W2019944441 startingPage "98" @default.
• W2019944441 abstract "Objective To determine the rationale for using stress ulcer prophylaxis (SUP) among clinicians; to assess criteria used to define failure of SUP; and to evaluate the decision-making process in the selection of a prophylactic agent. Design A cross-sectional national mail survey. Setting Random sample of the members of the Society of Critical Care Medicine who identified anesthesiology, surgery, or internal medicine as their primary specialty area. Patients None. Intervention None. Measurements and Main Results Questionnaires consisting of multiple-choice and short-answer questions were sent to a simple random sample of 1,268 physicians to assess the current practice of SUP. A total of 328 usable questions were returned, resulting in a response rate of 26%. All percentages reported in the results are based on the total number of responses. The risk factors for SUP that were most commonly identified were burns (91%), shock (90%), and sepsis (88%). These were also risk factors for which the respondents most commonly started SUP. Histamine-2-receptor (H2)-antagonists as a class, were the most commonly used prophylactic agents (67%). The most commonly used agents for SUP were ranitidine (31%), famotidine (24%), sucralfate (24%), and cimetidine (12%). Most respondents selected ranitidine for ease of administration, famotidine because of formulary availability, sucralfate for a better side effects profile, and cimetidine for cost-effectiveness. Eighty-two percent of respondents considered the presence of bright red blood in the nasogastric tube as failure of SUP. In cases where SUP failed, most respondents would add a second agent from a different therapeutic class. Of those respondents who used an H2-antagonist initially, 48% would add sucralfate, 36% would add antacid, and 13% would add omeprazole. Of those respondents who used sucralfate, 77% would add an H2-antagonist when SUP failed. For those respondents who would switch to another agent when the H2-antagonist failed, 52% would change to omeprazole, whereas 67% would change to an H2-antagonist when sucralfate failed. Only eight respondents would discontinue SUP when risk factors were resolved. Most respondents would discontinue SUP when the patient was no longer in the nothing by mouth status (28%), started on enteral feeding (23%), or discharged from the intensive care unit (21%). The mean duration of SUP was 6.3 +/- 4.5 (SD) days. Conclusions This survey highlighted the lack of consensus in the use of SUP. Many patients receive SUP for an extended period, without clear-cut indications or documented benefit. The cost of unwarranted SUP in patients with low risk of stress ulcer gastrointestinal bleeding is prohibitive. Treatment algorithms or protocols for SUP based on prescribing patterns, hospital formulary restrictions, and cost-analysis should be considered for each institution to guide critical care physicians on the proper use of SUP therapies. (Crit Care Med 1999; 27:98-103)" @default.
• W2019944441 created "2016-06-24" @default.
• W2019944441 creator A5011528472 @default.
• W2019944441 creator A5025086214 @default.
• W2019944441 creator A5049904756 @default.
• W2019944441 creator A5064000714 @default.
• W2019944441 date "1999-01-01" @default.
• W2019944441 modified "2023-10-13" @default.
• W2019944441 title "National survey of stress ulcer prophylaxis" @default.
• W2019944441 cites W1973117803 @default.
• W2019944441 cites W1975120233 @default.
• W2019944441 cites W1976500640 @default.
• W2019944441 cites W1978210068 @default.
• W2019944441 cites W1983899419 @default.
• W2019944441 cites W1984094645 @default.
• W2019944441 cites W2008574077 @default.
• W2019944441 cites W2008647255 @default.
• W2019944441 cites W2009742987 @default.
• W2019944441 cites W2016365628 @default.
• W2019944441 cites W2019725041 @default.
• W2019944441 cites W2024768254 @default.
• W2019944441 cites W2038043605 @default.
• W2019944441 cites W2050882826 @default.
• W2019944441 cites W2051270298 @default.
• W2019944441 cites W2055620951 @default.
• W2019944441 cites W2060186125 @default.
• W2019944441 cites W2075463212 @default.
• W2019944441 cites W2085994826 @default.
• W2019944441 cites W2106349983 @default.
• W2019944441 cites W2120044678 @default.
• W2019944441 cites W2125910885 @default.
• W2019944441 cites W2127494102 @default.
• W2019944441 cites W2151629261 @default.
• W2019944441 cites W2152957028 @default.
• W2019944441 cites W2198685361 @default.
• W2019944441 cites W2319207481 @default.
• W2019944441 cites W2321262375 @default.
• W2019944441 cites W2337267487 @default.
• W2019944441 cites W2401407247 @default.
• W2019944441 cites W4298770619 @default.
• W2019944441 doi "https://doi.org/10.1097/00003246-199901000-00034" @default.
• W2019944441 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9934901" @default.
• W2019944441 hasPublicationYear "1999" @default.
• W2019944441 type Work @default.
• W2019944441 sameAs 2019944441 @default.
• W2019944441 citedByCount "72" @default.
• W2019944441 countsByYear W20199444412012 @default.
• W2019944441 countsByYear W20199444412014 @default.
• W2019944441 countsByYear W20199444412016 @default.
• W2019944441 countsByYear W20199444412017 @default.
• W2019944441 countsByYear W20199444412018 @default.
• W2019944441 countsByYear W20199444412019 @default.
• W2019944441 countsByYear W20199444412020 @default.
• W2019944441 countsByYear W20199444412022 @default.
• W2019944441 crossrefType "journal-article" @default.
• W2019944441 hasAuthorship W2019944441A5011528472 @default.
• W2019944441 hasAuthorship W2019944441A5025086214 @default.
• W2019944441 hasAuthorship W2019944441A5049904756 @default.
• W2019944441 hasAuthorship W2019944441A5064000714 @default.
• W2019944441 hasConcept C126322002 @default.
• W2019944441 hasConcept C194828623 @default.
• W2019944441 hasConcept C20387591 @default.
• W2019944441 hasConcept C2776246392 @default.
• W2019944441 hasConcept C2777445857 @default.
• W2019944441 hasConcept C2779526319 @default.
• W2019944441 hasConcept C2780719153 @default.
• W2019944441 hasConcept C2781263782 @default.
• W2019944441 hasConcept C42219234 @default.
• W2019944441 hasConcept C512399662 @default.
• W2019944441 hasConcept C71924100 @default.
• W2019944441 hasConceptScore W2019944441C126322002 @default.
• W2019944441 hasConceptScore W2019944441C194828623 @default.
• W2019944441 hasConceptScore W2019944441C20387591 @default.
• W2019944441 hasConceptScore W2019944441C2776246392 @default.
• W2019944441 hasConceptScore W2019944441C2777445857 @default.
• W2019944441 hasConceptScore W2019944441C2779526319 @default.
• W2019944441 hasConceptScore W2019944441C2780719153 @default.
• W2019944441 hasConceptScore W2019944441C2781263782 @default.
• W2019944441 hasConceptScore W2019944441C42219234 @default.
• W2019944441 hasConceptScore W2019944441C512399662 @default.
• W2019944441 hasConceptScore W2019944441C71924100 @default.
• W2019944441 hasIssue "1" @default.
• W2019944441 hasLocation W20199444411 @default.
• W2019944441 hasLocation W20199444412 @default.
• W2019944441 hasOpenAccess W2019944441 @default.
• W2019944441 hasPrimaryLocation W20199444411 @default.
• W2019944441 hasRelatedWork W1923168725 @default.
• W2019944441 hasRelatedWork W2052864260 @default.
• W2019944441 hasRelatedWork W2068913337 @default.
• W2019944441 hasRelatedWork W2071434450 @default.
• W2019944441 hasRelatedWork W2149004754 @default.
• W2019944441 hasRelatedWork W2394627019 @default.
• W2019944441 hasRelatedWork W2404549882 @default.
• W2019944441 hasRelatedWork W2409351829 @default.
• W2019944441 hasRelatedWork W2416465000 @default.
• W2019944441 hasRelatedWork W2417954565 @default.
• W2019944441 hasVolume "27" @default.
• W2019944441 isParatext "false" @default.

• next